The therapeutic strategy based on a combinatorial blockage of MEK+BCL-XL/BCL2 is an active ongoing clinical trial for treating patients with advanced or metastatic solid tumors (https://clinicaltrials.gov/study/NCT02079740?cond=Solid%20Tumors&term=bcl-XL&limit=25&rank=3) and with recurrent ovarian and endometrial cancers (https://clinicaltrials.gov/study/NCT05691504?cond=Cancer&term=pelcitoclax&rank=2). This evidence concerns the gene BCL2 and endometrial cancer.